AD Pipeline Watch: UCB’s Galvokimig Passes Muster in Transcriptomic and Biomarker Analyses

Galvokimig (UCB) cools key inflammatory pathways implicated in atopic dermatitis (AD), according to a Phase 2a transcriptomics/biomarker analysis presented at the 2026 Congress of the European Academy of Dermatology and Venereology (EADV) in Vienna, Austria.